A recent study demonstrated that Benralizumab administration can be beneficial for both people with severe Chronic rhinosinusitis with nasal  polyps (CRSwNP) and severe eosinophilic asthma (SEA) from inflammatory and clinical perspectives.

Carlo Cavaliere et al. determined role of anti-IL5Rα  monoclonal antibody Benralizumab as a therapy option for management of concomitant SEA and CRSwNP. Furthermore, the authors elucidated Benralizumab's effect on cytological, hematological, clinical, and inflammatory parameters.

A total of 11 volunteers were retrospectively examined under add-on therapy with Benralizumab. In this pilot real-life study, assessment of symptoms was done with the aid of Asthma Control Test (ACT), Visual Analogue Scale (VAS), and Sino Nasal Outcome Test-22 (SNOT-22). Using Nasal Polyp Score (NPS) and Lund-Mackay Score (LMS), the Nasal polyp size was estimated. At six and twelve months, expression of cationic eosinophil protein (ECP), vascular endothelial growth factor (VEGF), interferon-gamma (INF-γ), and interleukin-17 was assessed by nasal scraping for examining inflammation of mucosa.

Following twelve months from commencing therapy, the LMS total score fell to 17 (8–21) from 21 (15–24). Following twelve months of Benralizumab use, the total VAS of rhinologic symptoms reduced from 30 (17–44) to 9 (5–37), SNOT-22 reduced from 45 (23–97) to 14 (5–53), while ACT scores raised from 10 (5–15) to 24 (20–25). Furthermore, NPS dropped from 5 (3–6) to 3 (2–4) following six months and to 2 (2–3) following one year.

The nasal mucosa scraping illustrated differences in  expression of INF-γ and VEGF in infected people versus 10 healthy volunteers. Benralizumab use elicited normalization of these biomarkers during eosinophils depletion.  Furthermore, this study indicated that VEGF and INF-γ may be promising response biomarkers. Hence, Benralizumab use was associated with significantly favorable effects on quality of life, disease control, symptoms, along with decrease in polyp size and inflammation of sinuses.